Table 3.
Most frequent adverse events
| AEs* | Experimental | Control | Total | Articles |
|---|---|---|---|---|
| Increased respiratory rate | 30 | 34 | 64 | [16] |
| Increased blood pressure | 20 | 20 | 40 | [16, 20, 26] |
| Fever | 17 | 22 | 39 | [15, 16, 20, 26] |
| Elevated ALT | 19 | 15 | 34 | [18, 20] |
| Anemia | 15 | 17 | 32 | [15, 16, 26] |
| Sepsis | 6 | 15 | 21 | [15, 16] |
| Deaths with no cause reported | 6 | 14 | 20 | [15, 16] |
| Decreased absolute lymphocyte | 8 | 9 | 17 | [16] |
| Elevated LDH | 10 | 7 | 17 | [18, 26] |
| Disease progression | 5 | 9 | 14 | [16] |
| Hypokalemia | 9 | 3 | 12 | [15, 18, 26] |
| Bacterial infections | 9 | 3 | 12 | [15, 18, 25] |
| Metabolic alkalosis | 5 | 6 | 11 | [16, 18] |
| Acute Respiratory Distress Syndrome | 4 | 7 | 11 | [16, 26] |
| Multiple organ failure | 3 | 8 | 11 | [16, 26] |
*AEs occurring a total of more than 10 times in all studies